Aegerion Pharmaceuticals Coverage Initiated at FBR Capital Markets (AEGR)
Equities research analysts at FBR Capital Markets initiated coverage on shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $111.00 price target on the stock. FBR Capital Markets’ target price suggests a potential upside of 34.05% from the company’s current price.
In other Aegerion Pharmaceuticals news, CEO Marc D. Beer sold 40,000 shares of the stock on the open market in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $87.79, for a total value of $3,511,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Aegerion Pharmaceuticals (NASDAQ:AEGR) opened at 82.802 on Wednesday. Aegerion Pharmaceuticals has a 52 week low of $19.07 and a 52 week high of $101.00. The stock has a 50-day moving average of $86.25 and a 200-day moving average of $74.25. The company’s market cap is $2.399 billion.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.07. The company had revenue of $16.30 million for the quarter, compared to the consensus estimate of $13.07 million. The company’s revenue for the quarter was up 1629900.0% on a year-over-year basis. On average, analysts predict that Aegerion Pharmaceuticals will post $-1.95 earnings per share for the current fiscal year.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.